Status:
UNKNOWN
COVID-19 Pathophysiology of Long Term Implications
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Conditions:
Covid19
Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Coronavirus disease 2019 (COVID 19) is primarily a respiratory viral infection. At the time of writing this protocol, more than 25 million people have been affected globally. Of these, more than 85000...
Detailed Description
COVID 19. A prospective case-control pathophysiological study of long term implications. The rationale of the study To identify the phenotype of patients who would have long term complications from C...
Eligibility Criteria
Inclusion
- Patients presenting with COVID symptoms to hospitals.
- Patients \>18 years old
Exclusion
- Patients without capacity to consent
- Pulmonary oedema secondary to decompensated cardiac, renal or liver disease at the time of admission
- Interstitial lung disease at the time of presentation
- Known lymphangitis carcinomatosis
- Morbidly obese patients with BMI more than 40
- Patients with known pulmonary hypertension or if the clinician feels there are other reasons for pulmonary hypertension than cardiomyopathy secondary to COVID 19.
- Pregnant women
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04813575
Start Date
August 1 2021
End Date
June 1 2022
Last Update
September 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia, 11211